Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Step by step instructions to Pick A Keep money with High Fixed Store Loan costs - 2Japan prepares to restart world's biggest nuclear plant, 15 years after Fukushima
- 3Cannabis reclassification could 'open the floodgates' for research, scientists say
- 4Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart?
- 5CDC clarifies stance on vaccines and autism, stating no evidence supports the link
- Director Emerald Fennell explains why "Wuthering Heights" has quotation marks around the title
- Well known Worldwide Caf\u00e9s to Experience
- Earth's newfound 'episodic-squishy lid' may guide our search for habitable worlds
- Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- Misjudged Objections For Solo Voyagers
- The Longest Underwater Tunnel Connecting Germany and Denmark
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- 6 Well known Nissan Vehicles in the U.S.
- ‘Everybody Loves Raymond: 30th Anniversary Reunion’ premiere date: How to watch, channel, time, cast and more
